Today's Pre-Open Stock Movers:

Agios Pharma (NASDAQ: AGIO) +35%; will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company.

RealPage (NASDAQ: RP) +31%; today announced it has entered into a definitive agreement to be acquired by Thoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector, in an all-cash transaction that values RealPage at approximately $10.2 billion, including net debt.

NantKwest (NASDAQ: NK) +31%; ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agreement to merge in a stock-for-stock transaction

Aerojet Rocketdyne (NYSE: AJRD) +26%; today announced that it has entered into a definitive agreement to be acquired by Lockheed Martin Corporation (NYSE: LMT) in an all-cash transaction with a total equity value of $5.0 billion.

Pivotal Investment Corp. II (NYSE: PIC) +22%

Corbus Pharma (NASDAQ: CRBP) +19%

Clovis Oncology (NASDAQ: CLVS) +13%; today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free survival (InvPFS) compared to chemotherapy in relapsed ovarian cancer patients with a tumor mutation of BRCA who have received two or more prior lines of chemotherapy.

Liminal BioSciences (NASDAQ: LMNL) +12%; Piper Sandler analyst Yasmeen Rahimi initiates coverage on Liminal BioSciences, Inc. (NASDAQ: LMNL) with a Overweight rating and a price target of $22.00.

Nike (NYSE: NKE) +5.8%; reported Q2 EPS of $0.78, $0.16 better than the analyst estimate of $0.62. Revenue for the quarter came in at $11.2 billion versus the consensus estimate of $10.56 billion.

JPMorgan (NYSE: JPM) +3.8%; Federal Reserve Board releases second round of bank stress test results, lets banks restart buybacks

• Related gainers include Citigroup (NYSE: C), Bank of America (NYSE: BAC), Goldman Sachs (NYSE: GS), Morgan Stanley (NYSE: MS), Wells Fargo (NYSE: WFC)

uniQure (NASDAQ: QURE) -20%; today announced that its hemophilia B gene therapy program, including the pivotal, Phase III HOPE-B study, has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Patient dosing is complete in each of uniQure’s three hemophilia B gene therapy studies, and there is no plan to enroll or treat additional patients.

Occidental Petroleum (NYSE: OXY) -9%; Oil tumbles as new virus strain revives demand worries

Norwegian Cruise Line (NYSE: NCLH) -7%; fast-spreading new coronavirus strain in Britain threatened to torpedo markets' optimism.

• Related decliners Carnival Corp. (NYSE: CCL), Royal Caribbean Group (NYSE: RCL), Delta Air Lines (NYSE: DAL), United Airlines (NASDAQ: UAL), American Airlines (NASDAQ: AAL)